lungevity.org
Jul 9, 2025, 07:30
New therapeutic option for patients whose disease has progressed on or after chemotherapy treatment – LUNGevity Foundation
LUNGevity Foundation shared a post on LinkedIn:
“FDA approval alert!
On July 2, 2025 the US FDA granted accelerated approval to sunvozertinib for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
This offers a new therapeutic option for patients whose disease has progressed on or after chemotherapy treatment. Learn more here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32